Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ.

Arthritis Rheumatol. 2019 May 9. doi: 10.1002/art.40921. [Epub ahead of print]

PMID:
31070869
2.

I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment.

Pavlidis S, Monast C, Loza MJ, Branigan P, Chung KF, Adcock IM, Guo Y, Rowe A, Baribaud F.

PLoS Comput Biol. 2019 Apr 30;15(4):e1006951. doi: 10.1371/journal.pcbi.1006951. eCollection 2019 Apr.

3.

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Sweet K, Dasgupta B, de Vries D, Gourley I, Hsu B, Loza MJ, Taylor PC.

Ann Rheum Dis. 2019 Oct;78(10):1439-1441. doi: 10.1136/annrheumdis-2019-215183. Epub 2019 Apr 24. No abstract available.

PMID:
31018960
4.

Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice.

Shen F, Verma AH, Volk A, Jones B, Coleman BM, Loza MJ, Malaviya R, Moore B, Weinstock D, Elloso MM, Gaffen SL, Ort T.

J Immunol. 2019 Apr 1;202(7):2017-2026. doi: 10.4049/jimmunol.1801436. Epub 2019 Feb 11.

PMID:
30745461
5.

Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort.

Emma R, Bansal AT, Kolmert J, Wheelock CE, Dahlen SE, Loza MJ, De Meulder B, Lefaudeux D, Auffray C, Dahlen B, Bakke PS, Chanez P, Fowler SJ, Horvath I, Montuschi P, Krug N, Sanak M, Sandstrom T, Shaw DE, Fleming LJ, Djukanovic R, Howarth PH, Singer F, Sousa AR, Sterk PJ, Corfield J, Pandis I, Chung KF, Adcock IM, Lutter R, Fabbella L, Caruso M; U-BIOPRED Study Group.

PLoS One. 2018 Sep 21;13(9):e0203874. doi: 10.1371/journal.pone.0203874. eCollection 2018.

6.

A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma.

Kollmeier AP, Barnathan ES, O'Brien C, Chen B, Xia YK, Zhou B, Loza MJ, Silkoff PE, Ge M, Thurmond RL.

Ann Allergy Asthma Immunol. 2018 Nov;121(5):568-574. doi: 10.1016/j.anai.2018.08.001. Epub 2018 Aug 11.

PMID:
30102965
7.

Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation.

Jevnikar Z, Östling J, Ax E, Calvén J, Thörn K, Israelsson E, Öberg L, Singhania A, Lau LCK, Wilson SJ, Ward JA, Chauhan A, Sousa AR, De Meulder B, Loza MJ, Baribaud F, Sterk PJ, Chung KF, Sun K, Guo Y, Adcock IM, Payne D, Dahlen B, Chanez P, Shaw DE, Krug N, Hohlfeld JM, Sandström T, Djukanovic R, James A, Hinks TSC, Howarth PH, Vaarala O, van Geest M, Olsson H; Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes study group.

J Allergy Clin Immunol. 2019 Feb;143(2):577-590. doi: 10.1016/j.jaci.2018.05.026. Epub 2018 Jun 11.

8.

Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma.

Kollmeier AP, Greenspan A, Xu XL, Silkoff PE, Barnathan ES, Loza MJ, Jiang J, Zhou B, Chen B, Thurmond RL.

Clin Exp Allergy. 2018 Aug;48(8):957-969. doi: 10.1111/cea.13154. Epub 2018 Jun 6.

PMID:
29682796
9.

IL-6 pathway upregulation in subgroup of severe asthma is associated with neutrophilia and poor lung function.

Turan N, Edwards MJ, Bates S, Shaw D, Chung KF, Loza MJ, James A, Van Oosterhout A; U-BIOPRED Study Group.

Clin Exp Allergy. 2018 Apr;48(4):475-478. doi: 10.1111/cea.13085. Epub 2018 Feb 19. No abstract available.

10.

Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation.

Silkoff PE, Singh D, FitzGerald JM, Eich A, Ludwig-Sengpiel A, Chupp GC, Backer V, Porsbjerg C, Girodet PO, Dransfield MT, Baribaud F, Susulic VS, Loza MJ.

Biomark Insights. 2017 Sep 7;12:1177271917730306. doi: 10.1177/1177271917730306. eCollection 2017.

11.

Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma.

Hekking PP, Loza MJ, Pavlidis S, De Meulder B, Lefaudeux D, Baribaud F, Auffray C, Wagener AH, Brinkman P, Lutter R, Bansal AT, Sousa AR, Bates SA, Pandis I, Fleming LJ, Shaw DE, Fowler SJ, Guo Y, Meiser A, Sun K, Corfield J, Howarth P, Bel EH, Adcock IM, Chung KF, Djukanovic R, Sterk PJ; U-BIOPRED Study Group.

Eur Respir J. 2017 Sep 27;50(3). pii: 1602298. doi: 10.1183/13993003.02298-2016. Print 2017 Sep.

12.

Pathway discovery using transcriptomic profiles in adult-onset severe asthma.

Hekking PP, Loza MJ, Pavlidis S, de Meulder B, Lefaudeux D, Baribaud F, Auffray C, Wagener AH, Brinkman P Ir, Lutter R Ir, Bansal AT, Sousa AR, Bates SA, Pandis Y, Fleming LJ, Shaw DE, Fowler SJ, Guo Y, Meiser A, Sun K, Corfield J, Howarth PH, Bel EH, Adcock IM, Chung KF, Djukanovic R, Sterk PJ; U-BIOPRED Study Group.

J Allergy Clin Immunol. 2018 Apr;141(4):1280-1290. doi: 10.1016/j.jaci.2017.06.037. Epub 2017 Jul 26.

13.

Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study.

Silkoff PE, Flavin S, Gordon R, Loza MJ, Sterk PJ, Lutter R, Diamant Z, Turner RB, Lipworth BJ, Proud D, Singh D, Eich A, Backer V, Gern JE, Herzmann C, Halperin SA, Mensinga TT, Del Vecchio AM, Branigan P, San Mateo L, Baribaud F, Barnathan ES, Johnston SL.

J Allergy Clin Immunol. 2018 Apr;141(4):1220-1230. doi: 10.1016/j.jaci.2017.06.027. Epub 2017 Jul 20.

14.

Integrating personalized gene expression profiles into predictive disease-associated gene pools.

Menche J, Guney E, Sharma A, Branigan PJ, Loza MJ, Baribaud F, Dobrin R, Barabási AL.

NPJ Syst Biol Appl. 2017 Mar 13;3:10. doi: 10.1038/s41540-017-0009-0. eCollection 2017.

15.

Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma.

Rossios C, Pavlidis S, Hoda U, Kuo CH, Wiegman C, Russell K, Sun K, Loza MJ, Baribaud F, Durham AL, Ojo O, Lutter R, Rowe A, Bansal A, Auffray C, Sousa A, Corfield J, Djukanovic R, Guo Y, Sterk PJ, Chung KF, Adcock IM; Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes (U-BIOPRED) Consortia Project Team.

J Allergy Clin Immunol. 2018 Feb;141(2):560-570. doi: 10.1016/j.jaci.2017.02.045. Epub 2017 May 18.

16.

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2018 Jan;77(1):21-29. doi: 10.1136/annrheumdis-2016-210456. Epub 2017 May 15.

17.

Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.

Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg CM, Girodet PO, Berger P, Kline JN, Chupp G, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study investigators.

J Allergy Clin Immunol. 2017 Sep;140(3):710-719. doi: 10.1016/j.jaci.2016.11.038. Epub 2017 Jan 13.

PMID:
28089872
18.

Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study.

Loza MJ, Djukanovic R, Chung KF, Horowitz D, Ma K, Branigan P, Barnathan ES, Susulic VS, Silkoff PE, Sterk PJ, Baribaud F; ADEPT (Airways Disease Endotyping for Personalized Therapeutics) and U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome Consortium) investigators.

Respir Res. 2016 Dec 15;17(1):165.

19.

Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study.

Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, Lefaudeux D, Auffray C, Loza MJ, Baribaud F, Fitch N, Sterk PJ, Chung KF, Gibeon D, Sun K, Guo YK, Adcock I, Djukanovic R, Dahlen B, Chanez P, Shaw D, Krug N, Hohlfeld J, Sandström T, Howarth PH; U-BIOPRED Study Group.

Eur Respir J. 2016 Nov;48(5):1307-1319. doi: 10.1183/13993003.01129-2016. Epub 2016 Oct 6.

20.

U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics.

Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, Bansal AT, Lutter R, Sousa AR, Corfield J, Pandis I, Bakke PS, Caruso M, Chanez P, Dahlén SE, Fleming LJ, Fowler SJ, Horvath I, Krug N, Montuschi P, Sanak M, Sandstrom T, Shaw DE, Singer F, Sterk PJ, Roberts G, Adcock IM, Djukanovic R, Auffray C, Chung KF; U-BIOPRED Study Group.

J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807. doi: 10.1016/j.jaci.2016.08.048. Epub 2016 Oct 20.

21.

Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.

Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; ADEPT Investigators.

Respir Res. 2016 Apr 23;17:43. doi: 10.1186/s12931-016-0360-5.

22.

Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies.

Loza MJ, Adcock I, Auffray C, Chung KF, Djukanovic R, Sterk PJ, Susulic VS, Barnathan ES, Baribaud F, Silkoff PE; ADEPT and U-BIOPRED Investigators.

Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S102-3. doi: 10.1513/AnnalsATS.201508-519MG.

23.

Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.

Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, Kelsen S, Eich A, Ludwig-Sengpiel A, Hupp GC, Backer V, Porsbjerg C, Girodet PO, Berger P, Leigh R, Kline JN, Dransfield M, Calhoun W, Hussaini A, Khatri S, Chanez P, Susulic VS, Barnathan ES, Curran M, Das AM, Brodmerkel C, Baribaud F, Loza MJ.

Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y.

24.

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, Petty KJ.

Br J Clin Pharmacol. 2013 May;75(5):1289-98. doi: 10.1111/j.1365-2125.2012.04477.x.

25.

Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.

Loza MJ, Watt R, Baribaud F, Barnathan ES, Rennard SI.

Respir Res. 2012 Feb 2;13:12. doi: 10.1186/1465-9921-13-12.

26.

T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.

Loza MJ, Anderson AS, O'Rourke KS, Wood J, Khan IU.

Cell Immunol. 2011;271(1):110-7. doi: 10.1016/j.cellimm.2011.06.010. Epub 2011 Jul 18.

27.

Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP.

Clin Vaccine Immunol. 2011 Jun;18(6):931-9. doi: 10.1128/CVI.00337-10. Epub 2011 Apr 20.

28.

Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype.

Silkoff PE, Loza MJ.

J Allergy Clin Immunol. 2011 Mar;127(3):834; author reply 834. doi: 10.1016/j.jaci.2010.10.046. Epub 2010 Dec 17. No abstract available.

PMID:
21167576
29.

Asthma and gender impact accumulation of T cell subtypes.

Loza MJ, Foster S, Bleecker ER, Peters SP, Penn RB.

Respir Res. 2010 Jul 28;11:103. doi: 10.1186/1465-9921-11-103.

30.

Regulation of T cells in airway disease by beta-agonist.

Loza MJ, Penn RB.

Front Biosci (Schol Ed). 2010 Jun 1;2:969-79. Review.

31.

Outcome after percutaneous endoscopic gastrostomy in children and young adults.

Fortunato JE, Troy AL, Cuffari C, Davis JE, Loza MJ, Oliva-Hemker M, Schwarz KB.

J Pediatr Gastroenterol Nutr. 2010 Apr;50(4):390-3. doi: 10.1097/MPG.0b013e3181aed6f1.

PMID:
20179645
32.

Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle.

Misior AM, Deshpande DA, Loza MJ, Pascual RM, Hipp JD, Penn RB.

Am J Respir Cell Mol Biol. 2009 Jul;41(1):24-39. doi: 10.1165/rcmb.2008-0266OC. Epub 2008 Dec 4.

33.

Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim ST, Zheng SL, Xu J, Isaacs WB, Chang BL.

Prostate. 2009 Feb 15;69(3):327-35. doi: 10.1002/pros.20882.

34.

Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells.

Loza MJ, Foster S, Peters SP, Penn RB.

J Allergy Clin Immunol. 2008 Mar;121(3):750.e1-5.e3. Epub 2007 Dec 21.

PMID:
18155275
35.

Assembly of inflammation-related genes for pathway-focused genetic analysis.

Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, Chang BL.

PLoS One. 2007 Oct 17;2(10):e1035.

36.

Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis.

Loza MJ, Chang BL.

J Allergy Clin Immunol. 2007 Sep;120(3):578-85. Epub 2007 Jun 21.

PMID:
17586032
37.

beta-Agonist enhances type 2 T-cell survival and accumulation.

Loza MJ, Peters SP, Foster S, Khan IU, Penn RB.

J Allergy Clin Immunol. 2007 Jan;119(1):235-44. Epub 2006 Oct 23.

PMID:
17208607
38.

Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells.

Loza MJ, Foster S, Peters SP, Penn RB.

Blood. 2006 Mar 1;107(5):2052-60. Epub 2005 Nov 8.

39.

Human peripheral CD2-/lo T cells: an extrathymic population of early differentiated, developing T cells.

Loza MJ, Luppi P, Kiefer K, Martin ES, Szczytkowski JL, Perussia B.

Int Immunol. 2005 Sep;17(9):1213-25. Epub 2005 Jul 18.

PMID:
16027135
40.

Atopy, asthma, and experimental approaches based on the linear model of T cell maturation.

Loza MJ, Peters SP, Penn RB.

Clin Exp Allergy. 2005 Jan;35(1):8-17. Review.

PMID:
15649260
41.

Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell.

Perussia B, Chen Y, Loza MJ.

Mol Immunol. 2005 Feb;42(4):385-95. Review.

PMID:
15607789
42.

Purification of peripheral blood natural killer cells.

Perussia B, Loza MJ.

Methods Mol Med. 2005;107:147-61. No abstract available.

PMID:
15492370
43.

The IL-12 signature: NK cell terminal CD56+high stage and effector functions.

Loza MJ, Perussia B.

J Immunol. 2004 Jan 1;172(1):88-96.

44.

Differential regulation of NK cell proliferation by type I and type II IFN.

Loza MJ, Perussia B.

Int Immunol. 2004 Jan;16(1):23-32.

PMID:
14688057
45.

Linear "2-0-1" lymphocyte development: hypotheses on cellular bases for immunity.

Perussia B, Loza MJ.

Trends Immunol. 2003 May;24(5):235-41. Review. No abstract available.

PMID:
12738416
46.
47.

Multiple color immunofluorescence for cytokine detection at the single-cell level.

Loza MJ, Faust JS, Perussia B.

Mol Biotechnol. 2003 Mar;23(3):245-58.

PMID:
12665694
48.

NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production.

Loza MJ, Metelitsa LS, Perussia B.

Eur J Immunol. 2002 Dec;32(12):3453-62.

49.

Supplemental Content

Support Center